Heart Failure, Periodic Breathing
Conditions
Keywords
Periodic breathing, Heart Failure, Chemoreflex, Chemosensitivity
Brief summary
We aim to test our method for measuring chemosensitivity (the ventilatory response to a change in carbon dioxide), which uses sinusoidal carbon dioxide stimuli. Hypotheses: * Carbon dioxide sensitivity is dependent on the cycle time over which we administer the gas (frequency). * Chemoreflex gain decreases as deadspace increases.
Detailed description
We will apply a new method for the measurement of chemosensitivity (how sensitive a person is to changes in carbon dioxide), which is one of the principle determinants of whether people with heart failure develop abnormal breathing patterns We have shown in a pilot study that administering sinusoidal patterns of inspired carbon dioxide produces similar sinusoidal responses in ventilation. We aim to test our method for measuring chemosensitivity, which uses sinusoidal carbon dioxide stimuli (similar to those that drive the oscillations in ventilation found in periodic breathing). We aim to show that how the cycle time of carbon dioxide administered affects the resulting ventilatory oscillations and therefore that when measuring the chemoreflex clinically, it is important to deliver carbon dioxide stimuli that replicate the cycle time of oscillations in carbon dioxide seen in periodic breathing (typically approximately one minute).
Interventions
OTHERcarbon dioxide
sinusoidal carbon dioxide administration
Sponsors
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Heart failure subjects with stable cardiorespiratory control to be recruited from our institution's specialist heart failure clinic. * Normal healthy volunteers, with normal systolic function.
Exclusion criteria
* We will exclude patients with chronic respiratory disease (every patient will have formal lung function testing on entrance into the study) or unstable coronary artery disease (myocardial infarction or unstable angina within the past 3 months). * In addition any subjects receiving treatment with morphine and derivatives, theophylline, oxygen, benzodiazepines or acetazolamide will be excluded as these affect chemosensitivity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemoreflex gain as measured by cyclocapnic method | every minute |
Countries
United Kingdom
Contacts
Primary ContactDarrel P Francis, MD
Outcome results
None listed